Apellis Pharmaceuticals Stock Hits 2-Year High After Biogen Merger
Apellis Pharmaceuticals (APLS) stock has reached a two-year high, showing a 140% upside following its merger with Biogen.
Results for "Apellis Pharmaceuticals"
7 stories found
Cantor Fitzgerald Lowers Price Target for Apellis Pharmaceuticals (APLS)
Cantor Fitzgerald has reduced its price target for Apellis Pharmaceuticals (APLS) from $35 to $31.
Apellis Pharmaceuticals Reports Q4 Earnings Call Highlights
Apellis Pharmaceuticals has released highlights from its fourth-quarter earnings call, detailing the company's financial results and pipeline progress.
Biogen Acquires Apellis for $5.6B, Expanding C3 Therapies Portfolio
Biogen has agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion, a deal that will expand Biogen's portfolio of rare-disease and kidney disease medicines by adding C3 therapies. The company is now detailing the deal, projecting mid-to-high-teens growth and EPS accretion by 2027.
Apellis Pharmaceuticals Receives New 'Buy' Rating from Roth
Apellis Pharmaceuticals has received a new 'Buy' rating from Roth, based on positive prospects for its drug Syfovre.
Biogen Acquires Apellis for $5.6 Billion in Rare Disease Expansion
Biogen is making a strategic move into the rare disease market with a $5.6 billion acquisition of Apellis Pharmaceuticals, aiming to expand its portfolio in this specialized area.
Apellis Pharmaceuticals Reports Q4 2025 Earnings
Apellis Pharmaceuticals, Inc. has provided a summary of its Q4 2025 earnings call.